Well differentiated neuroendocrine tumors, a single center experience

Abstract Purpose The aim of this study is to analyze the demographic, histopathologic features of Neuroendocrine tumor (NET) cases and to underline the treatment approaches over seven years period in a high-volume cancer center. Methods This study designed as a retrospective evaluation of NET registry data from a single medical oncology clinic between January 2012 and November 2017. Results A total of 72 patients'? data were registered. The median age was 54 (18–84) years. The three most common sites of diagnosis were pancreas (19 cases, 26.4%), unknown primary with liver metastasis (15 cases-20.8%) and lung (10–13.9%). There was no association between the extent of disease and grade of NET (p = 0.73). Apart from pancreatic NETs, there was no difference in the stages of disease presentation (p > 0.05). Globally, estimated 5-year overall survival (OS) rate was 77.5% and 10-year OS rate was 57.8%. There was no statistically significant difference in estimated 5- year OS rates of comparison between grade 1 and grade 2 NET's (69.9 vs. 91.8%, p = 0.19). In addition, Ki67 proliferative index did not make any difference in estimated 5- year OS rates (78.1 vs 77.7%, p = 0.71). Conclusions The multimodality treatment, site specific approaches and radionuclide therapies lead to better response rates and a longer survival in patients. Although there is a difference in distribution and presentation of NET cases compared to previous publications, optimal treatment yields a good Results?. Wherever possible, treatment of NETs is optimally scheduled by a multidisciplinary team, data collection should be centralized and audited by the team to make a clear conclusion for a less acknowledged tumor type.